ACCEPT DECLINE
Change Visitor Type Sign up to our newsletter

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

This article will open in a new window.Oxford Capital is not responsible for the content of third-party websites. Would you like to continue?

YesNo

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

By Oxford Capital |

Good news for our portfolio company, Oxford BioTherapeutics – OBT and WuXi Biologics have selected a second bispecific programme that will combine an anti-PD-L1 antibody with OBT’s immuno-oncology candidate, OX003.

Awards

  • BEST EIS
    FUND MANAGER
    2013,2012,2010 AND 2006

  • VENTURE CAPITAL
    HOUSE OF THE YEAR
    WINNER 2013 AND 2005

  • INVESTOR OF
    THE YEAR
    WINNER IN 2012 AND 2013

  • MOST IMPACTFUL
    INVESTMENT
    WINNER 2017

  • BEST ANGEL
    SYNDICATE
    WINNER 2018

  • BVCA Excellence in ESG
    GP CATEGORY
    COMMENDED 2020

  • VC INVESTOR OF THE YEAR
    GIANT HEALTH AWARDS
    WINNER 2020

  • EXIT OF THE YEAR
    ONE TO WATCH
    2020